CALGARY, Alberta, Oct. 9, 2025 — Hemostemix has filed for Institutional Review Board (IRB) approval of its Phase 1 clinical trial testing ACP-01, an autologous stem cell therapy for patients with vascular dementia. The 102-page submission marks a pivotal milestone toward addressing a condition that accounts for up to 20% of global dementia cases and currently has no approved treatment.
Science Significance
The investigational therapy, ACP-01, consists of angiogenic cell precursors derived from a patient’s own blood. These cells promote angiogenesis, neuroprotection, and vascular repair by releasing growth factors like VEGF and IL-8. Delivered directly into the cerebrospinal fluid via intrathecal injection, ACP-01 bypasses the blood–brain barrier, allowing targeted delivery to damaged brain regions. The study represents a first-in-class application of regenerative cell therapy to neurovascular disease, potentially opening new pathways in treating cognitive decline.
Regulatory Significance
The IRB submission initiates the ethics and safety review process required before clinical enrollment can begin. This Phase 1, multi-center, open-label study will evaluate the safety, feasibility, and preliminary efficacy of intrathecal ACP-01 administration in 20–100 participants aged 50–100. Key endpoints include adverse event monitoring, cognitive improvement (MoCA, MCI Screen), and MRI-based perfusion metrics. Approval of this protocol will enable first-in-human dosing and set the stage for potential FDA Investigational New Drug (IND) progression.
Business Significance
Advertisement
For Hemostemix, this step strengthens its position in cell-based regenerative medicine and diversifies its clinical pipeline beyond cardiovascular disease. ACP-01 has already shown safety and efficacy in chronic limb ischemia and ischemic cardiomyopathy, validating its angiogenic potential. Expanding into neuroscience applications may increase the company’s market value and attract new partnerships and investment in neuroregenerative therapies.
Patients’ Significance
For patients with vascular cognitive impairment, current options are limited to symptom management. If successful, ACP-01 could become a disease-modifying therapy, improving cerebral blood flow, memory, and cognition. By using the patient’s own cells, the treatment minimizes immune risk and maximizes safety — offering personalized, low-toxicity intervention for one of the most devastating aging-related diseases.
Policy Significance
This trial aligns with global dementia research policies emphasizing neurovascular repair and regenerative approaches. It supports public health goals to reduce the burden of dementia, enhance ethical clinical research transparency, and promote innovation in stem cell therapeutics. The ethical review process reinforces the importance of compliance with human research standards while advancing scientific progress.
Hemostemix’s IRB filing for its vascular dementia study marks an important regulatory and scientific milestone in regenerative neuroscience. By combining autologous stem cell therapy with targeted brain delivery, the company is pioneering a therapeutic frontier that could reshape the treatment landscape for dementia and neurodegenerative disease worldwide.
Source: Hemostemix Medical press release
